Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $39.75, Implies 17% Upside

Arcutis Biotherapeutics, Inc. saw its average price target raised by analysts from $39.12 to $39.75, with a range of $34 to $48. This implies a 17% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 8 analysts, with 7 Buys, 1 Hold, and 0 Sells.

Original reporting
Published Nov 5, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arcutis Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $39.75, Implies 17% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst consensus remains a Buy, with 7 Buys and 1 Hold, indicating continued confidence.

02

Market read

The price‑target increase may attract short‑term buying interest but is unlikely to cause a large move.

03

What to watch

Potential regulatory or clinical trial setbacks that are not reflected in the new target.

Relevance 5/10Novelty 5/10Timing: today

Background

Arcutis Biotherapeutics is a clinical-stage biotech focused on dermatology and immunology.

Market effects

May lift sentiment in the biotech sector as analysts show confidence in Arcutis.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; primarily relevant to investors tracking small-cap biotech stocks.

Counterpoint

The target raise could be premature if upcoming trial data disappoints.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Clinical-stage biotech company.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.